Published in Clin Vaccine Immunol on August 05, 2015
Host-to-Host Transmission of Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. Cell Host Microbe (2017) 1.39
Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life. Clin Vaccine Immunol (2016) 0.75
Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol (2017) 0.75
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (2009) 15.31
Serotype replacement in disease after pneumococcal vaccination. Lancet (2011) 7.14
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis (2011) 5.31
Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol (1997) 4.78
Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun (1983) 4.18
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis (2005) 3.76
Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis (2004) 3.43
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol (1997) 3.01
Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun (1994) 3.01
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med (2014) 2.88
Host cellular immune response to pneumococcal lung infection in mice. Infect Immun (2000) 2.74
Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog (2009) 2.69
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest (2009) 2.51
Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis (2003) 2.46
Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun (1991) 2.32
Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog (1994) 2.20
The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol (1996) 2.18
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine (1996) 2.08
Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem (2000) 2.05
Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect (1989) 2.00
23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec (2008) 1.92
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene (2002) 1.87
Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun (2003) 1.83
Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis (2014) 1.82
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis (1995) 1.78
Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface. Proc Natl Acad Sci U S A (2010) 1.66
Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun (2001) 1.62
Proinflammatory interactions of pneumolysin with human neutrophils. J Infect Dis (2001) 1.62
Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med (2008) 1.61
Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun (1999) 1.60
The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol (2011) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
Genomic analyses of pneumococci from children with sickle cell disease expose host-specific bacterial adaptations and deficits in current interventions. Cell Host Microbe (2014) 1.49
Solution structure of choline binding protein A, the major adhesin of Streptococcus pneumoniae. EMBO J (2004) 1.47
Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol (1998) 1.44
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog (1992) 1.39
Review: current and new generation pneumococcal vaccines. J Infect (2014) 1.29
Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children. J Infect Dis (2001) 1.25
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun (2010) 1.14
Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun (2002) 1.10
Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun (2001) 1.07
Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry (2000) 1.06
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun (2012) 0.97
Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood. Infect Immun (2011) 0.94
Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J Infect Dis (2013) 0.94
Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin. Infect Immun (2011) 0.91
The impact of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain-dependent. PLoS One (2014) 0.86
Development of cross-reactive antibodies to the proline-rich region of pneumococcal surface protein A in children. Vaccine (2012) 0.83
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine (2013) 0.83
Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in Streptococcus pneumoniae. Infect Immun (2014) 0.85
Role of copper efflux in pneumococcal pathogenesis and resistance to macrophage-mediated immune clearance. Infect Immun (2015) 0.80
Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC. Clin Vaccine Immunol (2014) 0.76
Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins. Clin Vaccine Immunol (2014) 0.75
A Perfect Storm: Increased Colonization and Failure of Vaccination Leads to Severe Secondary Bacterial Infection in Influenza Virus-Infected Obese Mice. MBio (2017) 0.75
A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus influenzae-Mediated Acute Otitis Media. Infect Immun (2019) 0.75